考虑到心脏病发作的大小和急性缺血性中风的功能结果,早期服用阿皮克萨班
Min Hwan Lee1, Jaseong Koo1, Hanim Kwon2
1Department of Neurology, Seoul St. Mary's Hospital, University of Catholic, Seoul, Republic of Korea.
Frontiers in neurology
|February 12, 2024
概括
对心房动中风患者的早期阿皮克萨班启动,以心脏病发作大小为指导,改善功能结果和减少中风复发. 这一策略增强了恢复,而没有增加出血转化风险.
科学领域:
- 神经科学是一个神经科学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与心房相关的中风 (心房中风) 预后不佳,以进展,复发和出血转变为标志.
- 优化抗凝策略对于改善急性AF中风患者的治疗结果至关重要.
研究的目的:
- 为了研究分层早期apixaban在急性AF中风患者中的疗效.
- 评估心脏病发作大小对早期开始服用阿皮克萨班后功能结果的影响.
主要方法:
- 分析了接受阿皮克萨班的急性AF中风患者队列.
- 患者根据心脏病发作的大小 (小,中,大) 和apixaban启动时间 (标准与早期) 分层.
- 结果包括功能状态 (修改的兰金尺度),中风进展,复发和症状出血转变 (sHT) 进行了比较.
主要成果:
- 早期启动阿皮克萨班与显著更高的良好功能结果相关 (61.8%与48.1%,p=0.019).
- 早期启动组的中风进展或早期复发较少 (4.7%对13.2%,p=0.007).
- 两组之间没有观察到症状出血转变的显著差异.
结论:
- 考虑到心脏病发作的大小,分层早期服用阿皮克萨班是一种有前途的策略,可以增强AF中风后的功能恢复.
- 这种方法可以减少中风的进展和复发,而不会增加出血并发症的风险.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
524
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
524


